Atumelnant for adults with classic CAH
Treatments studied
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have classic congenital adrenal hyperplasia (CAH) caused by 21-OHD.
- You must be between 18 and 74 years old.
- Your glucocorticoid dose must be stable (no major changes) for at least 2 months before joining.
- Your morning blood test for a hormone called A4 must fall within certain ranges depending on your glucocorticoid dose.
- You cannot have had both adrenal glands removed or have conditions that need long-term steroid treatment besides CAH.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This study tests the long-term safety and effectiveness of the study drug atumelnant for people with congenital adrenal hyperplasia. It is for those who have already completed a previous atumelnant study and may benefit from continuing treatment.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
This trial studies whether a once-daily hydrocortisone tablet works as well as standard steroid treatment for adults with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. It aims to improve how safely and conveniently hormone replacement is taken each day.
This study looks at the long-term experiences of adults with classic congenital adrenal hyperplasia (CAH), a condition affecting hormone production. It aims to understand patient satisfaction and health outcomes over time.
Hear when a new Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.